Citigroup Maintains Neutral on Haemonetics, Lowers Price Target to $85
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Joanne Wuensch maintains a Neutral rating on Haemonetics (NYSE:HAE) and lowers the price target from $94 to $85.
August 22, 2024 | 3:44 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Citigroup has maintained its Neutral rating on Haemonetics but lowered the price target from $94 to $85, indicating a less optimistic outlook.
The lowering of the price target by Citigroup suggests a less optimistic view on Haemonetics' future performance, which could lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100